[ad_1]
Shares of pharmaceutical giant Moderna (MRNA) are falling after the company released efficacy data for its RSV vaccine. Yahoo Finance’s Breaking News examines the reported long-term efficacy of the latest vaccine being developed by Moderna.
For more expert insights and the latest market trends, click here to watch the full episode of Yahoo Finance Live.
Editor’s note: This article was written by luke carberry morgan.
video transcript
– Let’s talk about Moderna. These stocks are falling today after the company announced that the statistics for its experimental RSV shot were worse than previous data. That has Wall Street analysts worried that the vaccine’s effectiveness will decline more quickly when compared to competing vaccines from Pfizer and GSK.
The stock price fell about 7%. RSV is a virus that is especially harmful to the elderly, including young children. There are concerns about its spread. And indeed, these results seem to indicate that protection against RSV diminishes the further away you are from the shot, although it is not clear why this is the case. And it seems like people are still trying to sift through this data.
– The other headline I saw today was this kind of patent battle going on with Orbitz, which was also very interesting. And I think that sounds like there’s some concern about the technology of using this coronavirus vaccine. That also attracted a lot of interest. And analysts were trying to come up with some numbers around that.
For example, Bloomberg analyst Julie said he believes Moderna actually faces an uphill battle to avoid liability in the patent battle. So I know that was another headline that made the news. Moderna, I’m looking at the stock, it’s down about 10% this year and it’s down about 45% right now over the past 12 months.
– Yes, investors want more from Moderna, and yes, the company says there’s more coming to market and more revenue to come.
[ad_2]
Source link
